Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02159053) enrolled 350 people in total across three groups: 116 received secukinumab 150 mg with a "loading dose" (extra doses at the start), 117 received secukinumab 150 mg without a loading dose, and 117 received a placebo (an inactive treatment). The trial was measuring how people with ankylosing spondylitis — a type of inflammatory spinal condition — responded to the medication compared to placebo, using a range of standardised questionnaires and blood tests over 16 weeks. The reported data shows that for the main outcome — the proportion of participants who met a standard set of improvement criteria across four areas (overall disease activity, back pain, physical function, and morning stiffness) — 60.5% in the loading-dose group, 65.5% in the no-loading-dose group, and 49.1% in the placebo group reached that threshold at 16 weeks. For a stricter version of those same criteria (requiring greater improvement), the reported figures were 39.5%, 38.2%, and 29.5% respectively. A blood marker linked to inflammation (high-sensitivity C-reactive protein) showed reported average changes of −4.23 and −6.57 (in ratio units) for the two secukinumab groups, compared to +0.62 for the placebo group. On a disease activity score (rated 0–10, where higher means worse), the reported average reductions from starting scores were approximately 2.4 and 2.5 points for the secukinumab groups, and 1.9 points for the placebo group. A physical quality-of-life score (where higher numbers mean less disability) showed reported average increases of about 6.8 and 7.2 points in the secukinumab groups, and 4.7 points in the placebo group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41965705) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Ankylosing Spondylitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with moderate to severe ankylosing spondylitis (a type of inflammatory spinal arthritis)
- Past X-rays have confirmed your diagnosis based on specific medical imaging guidelines from 1984 (confirm with trial site)
- Pain relief medications known as NSAIDs (such as ibuprofen or naproxen) have not worked well enough to control your symptoms
Who may not be able to join:
- You are currently pregnant or breastfeeding
- A chest X-ray or MRI scan shows signs of an active infection or cancer
- You have previously been treated with certain targeted therapies that affect a protein called IL-17 or its receptor (confirm with trial site)
- You have previously used any biological medication that affects the immune system, with the exception of TNF blocker treatments (a specific type of immune therapy)
- You have previously had a treatment designed to remove or reduce certain immune cells from your body (confirm with trial site)
Please note that there are additional eligibility requirements beyond those listed here that the trial team will also need to check.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Responded for Assessment of Spondyloarthritis International Society 20 Criteria (ASAS20) at 16 Weeks
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.